Cargando…

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

BACKGROUND: In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression. An additio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díaz-Rubio, Eduardo, Gómez-España, Auxiliadora, Massutí, Bartomeu, Sastre, Javier, Reboredo, Margarita, Manzano, José Luis, Rivera, Fernando, Safont, MªJosé, Montagut, Clara, González, Encarnación, Benavides, Manuel, Marcuello, Eugenio, Cervantes, Andrés, Martínez de Prado, Purificación, Fernández-Martos, Carlos, Arrivi, Antonio, Bando, Inmaculada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470549/ https://www.ncbi.nlm.nih.gov/pubmed/23174912 http://dx.doi.org/10.1371/journal.pone.0047345

Ejemplares similares

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
por: Benavides, Manuel, et al.
Publicado: (2019)

SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)
por: Capdevila, Jaume, et al.
Publicado: (2022)

Correction to: SEOM‑GEMCAD‑TTD clinical guidelines for localized rectal cancer (2021)
por: Capdevila, Jaume, et al.
Publicado: (2022)

Update of TTD: Therapeutic Target Database
por: Zhu, Feng, et al.
Publicado: (2010)

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
por: Carrato, A., et al.
Publicado: (2019)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

Transient Triplet Differential (TTD) Method for Background Free Photoacoustic Imaging
por: Tan, Joel W. Y., et al.
Publicado: (2018)

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
por: Elez, Elena, et al.
Publicado: (2019)

A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features
por: Salazar, Ramon, et al.
Publicado: (2015)

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
por: Fernández-Montes, Ana, et al.
Publicado: (2022)

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results
por: Salazar, Ramón, et al.
Publicado: (2020)

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
por: Fernández Montes, Ana, et al.
Publicado: (2023)

Homeostatic Imbalance between Apoptosis and Cell Renewal in the Liver of Premature Aging Xpd(TTD) Mice
por: Park, Jung Yoon, et al.
Publicado: (2008)

Correction: Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
Publicado: (2020)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
por: Vivancos, Ana, et al.
Publicado: (2019)

Targeted Therapy Database (TTD): A Model to Match Patient's Molecular Profile with Current Knowledge on Cancer Biology
por: Mocellin, Simone, et al.
Publicado: (2010)

The GTP- and Phospholipid-Binding Protein TTD14 Regulates Trafficking of the TRPL Ion Channel in Drosophila Photoreceptor Cells
por: Cerny, Alexander C., et al.
Publicado: (2015)

In vitro characterization of a pAgo nuclease TtdAgo from Thermococcus thioreducens and evaluation of its effect in vivo
por: Tang, Ying, et al.
Publicado: (2023)

Non-invasive evaluation of transdermal drug delivery using 3-D transient triplet differential (TTD) photoacoustic imaging
por: Xie, Yang, et al.
Publicado: (2023)

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
por: Martinez-Balibrea, E, et al.
Publicado: (2010)

Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab
por: Ortiz-Morales, M. José, et al.
Publicado: (2022)

Conformational dynamics of the TTD–PHD histone reader module of the UHRF1 epigenetic regulator reveals multiple histone-binding states, allosteric regulation, and druggability
por: Houliston, R. Scott, et al.
Publicado: (2017)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
por: Pathak, Surajit, et al.
Publicado: (2017)

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study
por: Huang, Chunlong, et al.
Publicado: (2021)

Association between the Preoperative Dietary Antioxidant Index and Postoperative Quality of Life in Patients with Esophageal Squamous Cell Carcinoma: A Prospective Study Based on the TTD Model
por: Zhang, Juwei, et al.
Publicado: (2023)

Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
por: Nogueras, MaMercedes, et al.
Publicado: (2006)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
por: García-Alfonso, Pilar, et al.
Publicado: (2015)

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
por: Bencsikova, Beatrix, et al.
Publicado: (2015)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
por: Shitara, Kohei, et al.
Publicado: (2016)

Infección tuberculosa de localización infrecuente
por: Betrán, Ana, et al.
Publicado: (2020)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
por: Provencio, Mariano, et al.
Publicado: (2022)

Reliability of INTERMED Spanish version and applicability in liver transplant patients: a cross-sectional study
por: Lobo, Elena, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_k0ja6kl6havv19v2tqvmftr3sf